Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information


Fremont, USA
34175 Ardenwood Blvd.
Fremont, CA, 94555


CEO & Board of Director
Co-Founder and Director
Vice President, Chemistry
Vice President, Drug Development
Vice President, Legal
Board Member
Board of Directors
Sr. Director Regulatory Affairs and Quality Assurance
Show All People


Series B, 8/2011
New Enterprise Associates
CMEA Capital
Debt, 11/2010



Ardelyx develops novel, first-in-class oral therapeutics to correct mineral metabolism and metabolic disorders. The Company’s molecules, whose systemic exposure is severely restricted, target transporters and receptors, modulating the uptake of nutrients or inducing secretion of key hormones to produce a therapeutic benefit in patients. The Company’s non-systemic products act from within the intestines to avoid potential side effects that could occur with systemic exposure. The Company’s lead product, RDX5791, a minimally-absorbed, orally administered NHE3 sodium transport inhibitor, is being developed both for constipation-predominant irritable bowel syndrome (IBS-C) and for prevention of excess dietary sodium absorption, a new treatment modality for high blood pressure. RDX5791 is in phase 2 for IBS-C and a dose-ranging/regimen study for inhibition of excess dietary sodium absorption. Ardelyx is also developing RDX002, a minimally-absorbed, orally administered NaP2b phosphate transport inhibitor for the inhibition of phosphate absorption in patients with chronic kidney disease, and RDX009, a minimally-absorbed, orally administered TGR5 agonist for the treatment of type 2 diabetes through direct induction of intestinal incretins such as GLP-1 and PYY. Both RDX002 and RDX009 are in preclinical development. To date, Ardelyx has raised $56M in venture and angel funding since it was founded in 2007. Ardelyx is located in Fremont, California.

Recent Milestones

  • Check
    Ardelyx — Ardelyx Receives $15 Million Milestone as Part of Ongoing Tenapanor Collaboration With AstraZeneca (1/13/14)
    Posted 1/13/14 at 10:42pm via
  • Dollar
    Ardelyx received $30M in Series B funding. (8/31/11)
    Posted 8/31/11 at 6:21pm via
  • Dollar
    Ardelyx received $5.01M in Debt funding. (11/16/10)
    Posted 1/20/14 at 2:55am via
  • Check
    Ardelyx added Mike Raab as CEO & Board of Director.
    Posted 8/31/11 at 6:21pm
  • Check
    Ardelyx added Peter G. Schultz as Co-Founder and Director.
    Posted 11/1/13 at 8:28pm



Ardelyx screenshot
Above: Ardelyx
Uploaded: 3/12/13


  1. SEC ( [edit]
  2. Ardelyx, Inc. Closes $30M Series B Financing ( [edit]
  3. Ardelyx Receives $15 Million Milestone as Part of Ongoing Tenapanor Collaboration With AstraZeneca ( [edit]
Edit This Page
Last Edited 1/20/14

Revision History RSS Picture


Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API


Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy